Intralesional cis-diamminedichloroplatinum and purified collagen treatment of human metastatic malignancies: a feasibility study

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

A feasibility study of the treatment of advanced superficial human malignant tumors utilizing direct intralesional injections of cisplatin mixed with purified bovine collagen was performed. The purpose of using intralesional injection of cisplatin mixed with collagen was to limit the drug exposure to normal tissues while increasing the dose and duration of exposure to the tumor. Fourteen evaluable superficial tumors in four patients (melanoma, breast CA, squamous CA from larynx) received a total of 65 treatments in the outpatient clinic setting. All patients had failed prior treatment with systemic intravenous cisplatin. Lesions were treated at least three times at two-week intervals. After intramuscular meperidine premedication, multiple injections of cisplatin mixed with collagen were made into the tumors. There was minimal normal tissue toxicity and minimal systemic toxicity. Tumor regression or stabilization occurred in 86% (12/14) of tumors; 50% (7/14) of lesions regressed more than 50% in size. This study suggests that intralesional colloidal cisplatin can overcome resistance to systemic intravenous cisplatin.

Original languageEnglish (US)
Pages (from-to)83-87
Number of pages5
JournalJournal of Surgical Oncology
Volume43
Issue number2
StatePublished - 1990

Fingerprint

Feasibility Studies
Cisplatin
Collagen
Intralesional Injections
Neoplasms
Therapeutics
Meperidine
Premedication
Larynx
Ambulatory Care Facilities
Melanoma
Breast
Injections
Pharmaceutical Preparations

Keywords

  • Cisplatin
  • matrix
  • regional chemotherapy

ASJC Scopus subject areas

  • Oncology
  • Surgery

Cite this

@article{89315d080d7449caa5905d95f93e05de,
title = "Intralesional cis-diamminedichloroplatinum and purified collagen treatment of human metastatic malignancies: a feasibility study",
abstract = "A feasibility study of the treatment of advanced superficial human malignant tumors utilizing direct intralesional injections of cisplatin mixed with purified bovine collagen was performed. The purpose of using intralesional injection of cisplatin mixed with collagen was to limit the drug exposure to normal tissues while increasing the dose and duration of exposure to the tumor. Fourteen evaluable superficial tumors in four patients (melanoma, breast CA, squamous CA from larynx) received a total of 65 treatments in the outpatient clinic setting. All patients had failed prior treatment with systemic intravenous cisplatin. Lesions were treated at least three times at two-week intervals. After intramuscular meperidine premedication, multiple injections of cisplatin mixed with collagen were made into the tumors. There was minimal normal tissue toxicity and minimal systemic toxicity. Tumor regression or stabilization occurred in 86{\%} (12/14) of tumors; 50{\%} (7/14) of lesions regressed more than 50{\%} in size. This study suggests that intralesional colloidal cisplatin can overcome resistance to systemic intravenous cisplatin.",
keywords = "Cisplatin, matrix, regional chemotherapy",
author = "Krag, {D. N.} and Theon, {Alain P} and Schneider, {Philip D} and {Goodnight Jr}, {James E}",
year = "1990",
language = "English (US)",
volume = "43",
pages = "83--87",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Intralesional cis-diamminedichloroplatinum and purified collagen treatment of human metastatic malignancies

T2 - a feasibility study

AU - Krag, D. N.

AU - Theon, Alain P

AU - Schneider, Philip D

AU - Goodnight Jr, James E

PY - 1990

Y1 - 1990

N2 - A feasibility study of the treatment of advanced superficial human malignant tumors utilizing direct intralesional injections of cisplatin mixed with purified bovine collagen was performed. The purpose of using intralesional injection of cisplatin mixed with collagen was to limit the drug exposure to normal tissues while increasing the dose and duration of exposure to the tumor. Fourteen evaluable superficial tumors in four patients (melanoma, breast CA, squamous CA from larynx) received a total of 65 treatments in the outpatient clinic setting. All patients had failed prior treatment with systemic intravenous cisplatin. Lesions were treated at least three times at two-week intervals. After intramuscular meperidine premedication, multiple injections of cisplatin mixed with collagen were made into the tumors. There was minimal normal tissue toxicity and minimal systemic toxicity. Tumor regression or stabilization occurred in 86% (12/14) of tumors; 50% (7/14) of lesions regressed more than 50% in size. This study suggests that intralesional colloidal cisplatin can overcome resistance to systemic intravenous cisplatin.

AB - A feasibility study of the treatment of advanced superficial human malignant tumors utilizing direct intralesional injections of cisplatin mixed with purified bovine collagen was performed. The purpose of using intralesional injection of cisplatin mixed with collagen was to limit the drug exposure to normal tissues while increasing the dose and duration of exposure to the tumor. Fourteen evaluable superficial tumors in four patients (melanoma, breast CA, squamous CA from larynx) received a total of 65 treatments in the outpatient clinic setting. All patients had failed prior treatment with systemic intravenous cisplatin. Lesions were treated at least three times at two-week intervals. After intramuscular meperidine premedication, multiple injections of cisplatin mixed with collagen were made into the tumors. There was minimal normal tissue toxicity and minimal systemic toxicity. Tumor regression or stabilization occurred in 86% (12/14) of tumors; 50% (7/14) of lesions regressed more than 50% in size. This study suggests that intralesional colloidal cisplatin can overcome resistance to systemic intravenous cisplatin.

KW - Cisplatin

KW - matrix

KW - regional chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=0025263825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025263825&partnerID=8YFLogxK

M3 - Article

C2 - 2304345

AN - SCOPUS:0025263825

VL - 43

SP - 83

EP - 87

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 2

ER -